eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021 Fast Track designation granted by the ...

This study is the first time an eIF2B activator has been administered to people with VWM disease. For more information on study NCT05757141, please visit: www.clinicaltrials.gov.

DNL343 is an investigational, small molecule eIF2B activator designed to cross the BBB with the potential of preventing or slowing ALS disease progression. The DNL343 abstract is available here on ...

DNL343, an eIF2B activator, is being evaluated in a phase II/III HEALEY study to treat ALS. Enrollment has been completed in Regimen G of the study. Denali and partner Sanofi SNY are co-developing ...

Dosing is currently ongoing. DNL343, an eIF2B activator, is being evaluated in a phase II/III HEALEY study to treat amyotrophic lateral sclerosis (ALS).

Vanishing white matter disease (VWM) is a rare and progressive leukoencephalopathy caused by loss-of-function mutations, in a recessive pattern of inheritance, in any of the genes encoding eIF2B, a ...